Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

Clinical Trial ID NCT00314262

PubWeight™ 2.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00314262

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013 1.02
2 Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia. Br J Cancer 2013 0.86
3 Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol 2013 0.81
Next 100